Gunilla Anders Ekström

Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden.

Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway.

NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden.

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Immuneed AB develops drugs. The firm offers as a contract research organization and provides specialized services for immunotoxicology and immunophenotyping. Its services include cytokine release assay, complement activation, cellular drug biodistribution, cell activation patterns, immune recall responses, viability analyses, blood status and mode-of-action studies. The company was founded by Sara Mangsbo, Erika Fletcher and Thomas Totterman in 2014 and is headquartered in Uppsala, Sweden.

Haracon AB provides corporate consulting services.

Disruptive Materials AB manufactures mesoporous magnesium carbonate. It focuses on commercializing the material Upsalite that can be used in applications such as desiccant for humidity control, pharmaceutics, adsorbent for waste handling, thermal and acoustic insulation, cosmetics, adsorbent in ink jet paper,and bio material applications. The company was founded by Johan A. V. Gómez de la Torre, Maria Strømme, Lars-Erik Mattias Karls, and Sara Kristina Frykstrand Ångström in December 2011 and is headquartered in Uppsala, Sweden.

Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden.

Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021.

Disruptive Pharma AB is a pharmaceutical company based in Uppsala, Sweden, with a passion for innovation in drug products. The Swedish company has perfected the groundbreaking mesoporous magnesium carbonate (mmc) drug delivery technology, which makes it easier to develop amorphous drug candidates. By combining the mmc formulation technology with drug compounds, they can enhance existing products or assist in formulating new therapies. Disruptive Pharma seeks commercial partnership or licensing to industry partners within the drug improvement business area. The company was founded in 2018 by Maria Strömme, and the CEO is Peter Åsberg.